Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.5M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$171M |
Are Oramed Pharmaceuticals Insiders Buying or Selling?
Oramed Pharmaceuticals (ORMP) has had 2 insider transactions in the past 90 days, all sells. The most recent was Avraham Gabay, who sold 20,000 shares at $4.51 on October 1, 2026.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the ORMP AI Score. For government officials trading this stock, see ORMP congressional trading.
Who’s Trading Oramed Pharmaceuticals Stock?
| Insider | Activity | Trades | Last Trade |
|---|---|---|---|
| Joshua Hexter | Sold $750,000 | 2 | Oct 1, 2026 |
| Avraham Gabay | Sold $420,000 | 2 | Oct 1, 2026 |
Recent Oramed Pharmaceuticals Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Avraham Gabay | Oct 1, 2026 | Sell | 20,000 | $4.51 | $90,000 |
| Joshua Hexter | Oct 1, 2026 | Sell | 30,000 | $4.51 | $140,000 |
| Joshua Hexter | Jul 1, 2026 | Sell | 137,000 | $4.46 | $610,000 |
| Avraham Gabay | Jul 1, 2026 | Sell | 73,360 | $4.51 | $330,000 |
Frequently Asked Questions: Oramed Pharmaceuticals Insider Trading
In the past 90 days, Oramed Pharmaceuticals insiders have made 0 buys and 2 sells. The net selling may indicate insiders are taking profits or reducing exposure.
The most recent sale was by Avraham Gabay who sold 20,000 shares on October 1, 2026. View all transactions in the table on this page.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Hexter Joshua has sold the most ORMP stock in the last 2 years, with a total value of $750,000.
The total value of insider transactions for Oramed Pharmaceuticals in the last 2 years is negative, amounting to -$1.2M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
